Literature DB >> 24415351

Behçet's syndrome pathophysiology and potential therapeutic targets.

Giacomo Emmi1, Elena Silvestri, Danilo Squatrito, Mario Milco D'Elios, Lucia Ciucciarelli, Domenico Prisco, Lorenzo Emmi.   

Abstract

Behçet syndrome is a systemic inflammatory disorder characterized by multiorgan involvement such as oral and genital ulcers, uveitis, skin lesions as well as by less frequent, but often more severe, central nervous system and vascular manifestations. The pathogenetic mechanisms are still incompletely known; however the interaction between a specific genetic background and environmental or infectious factors certainly contributes to the immune dysregulation that characterizes this disease. The discovery of new immunological pathways in Behçet syndrome pathogenesis may help us to set up new treatments. In this review, we will focus our attention on the possible mechanisms underlying Behçet syndrome pathogenesis and their potential role as novel therapeutic targets.

Entities:  

Mesh:

Year:  2014        PMID: 24415351     DOI: 10.1007/s11739-013-1036-5

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  73 in total

1.  Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.

Authors:  Shigeru Iwata; Kazuyoshi Saito; Kunihiro Yamaoka; Shizuyo Tsujimura; Masao Nawata; Katsunori Suzuki; Yoshiya Tanaka
Journal:  Rheumatology (Oxford)       Date:  2009-05-22       Impact factor: 7.580

2.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.

Authors:  Ahmet Gül; Ilknur Tugal-Tutkun; Charles A Dinarello; Leonid Reznikov; Bahar Artim Esen; Amer Mirza; Patrick Scannon; Alan Solinger
Journal:  Ann Rheum Dis       Date:  2011-11-14       Impact factor: 19.103

3.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

4.  Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease.

Authors:  S Buldanlioglu; S Turkmen; H B Ayabakan; N Yenice; M Vardar; S Dogan; E Mercan
Journal:  Br J Dermatol       Date:  2005-09       Impact factor: 9.302

5.  Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques.

Authors:  Marisa Benagiano; Mario M D'Elios; Amedeo Amedei; Annalisa Azzurri; Ruurd van der Zee; Alessandra Ciervo; Gianni Rombolà; Sergio Romagnani; Antonio Cassone; Gianfranco Del Prete
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

6.  Cytokine profile in Behçet uveitis.

Authors:  Selim Nalbant; Burak Sahan; Murat Durna; Dilaver Ersanli; Mustafa Kaplan; Ozlem Karabudak; Melih Unal
Journal:  Bratisl Lek Listy       Date:  2008       Impact factor: 1.278

Review 7.  Current and future treatments for Behçet's uveitis: road to remission.

Authors:  Marina Mesquida; Blanca Molins; Victor Llorenç; María Victoria Hernández; Gerard Espinosa; Andrew D Dick; Alfredo Adán
Journal:  Int Ophthalmol       Date:  2013-06-01       Impact factor: 2.031

8.  Serum BAFF levels and skin mRNA expression in patients with Behçet's disease.

Authors:  K Hamzaoui; H Houman; I Ben Dhifallah; M Kamoun; A Hamzaoui
Journal:  Clin Exp Rheumatol       Date:  2008 Jul-Aug       Impact factor: 4.473

9.  Skin prick test with self-saliva in patients with oral aphthoses: a diagnostic pathergy for Behcet's disease and recurrent aphthosis.

Authors:  Ari Togashi; Sanae Saito; Fumio Kaneko; Koichiro Nakamura; Noritaka Oyama
Journal:  Inflamm Allergy Drug Targets       Date:  2011-06

10.  Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis.

Authors:  Shunsei Hirohata; Hirotoshi Kikuchi; Tetsuji Sawada; Hiroko Nagafuchi; Masataka Kuwana; Mitsuhiro Takeno; Yoshiaki Ishigatsubo
Journal:  Mod Rheumatol       Date:  2011-09-21       Impact factor: 3.023

View more
  19 in total

1.  The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Anna De Palma; Ida Orlando; Stefano Gentileschi; Jurgen Sota; Antonella Simpatico; Claudia Fabiani; Mauro Galeazzi; Bruno Frediani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

2.  Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study.

Authors:  Claudia Fabiani; Antonio Vitale; Ida Orlando; Jurgen Sota; Marco Capozzoli; Rossella Franceschini; Mauro Galeazzi; Gian Marco Tosi; Bruno Frediani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2017-06-15       Impact factor: 3.397

3.  Transcatheter embolotherapy of pulmonary artery aneurysms as emergency treatment of hemoptysis in Behcet patients: experience of a referral center and a review of the literature.

Authors:  Guillaume Voiriot; Antoine Parrot; Martine Antoine; Aude Gibelin; Samuel Haddad; Marie-France Carette; Muriel Fartoukh; Antoine Khalil
Journal:  Intern Emerg Med       Date:  2018-03-07       Impact factor: 3.397

Review 4.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

5.  Interleukin 18, soluble cluster of differentiation 40, platelet factor 4 variant 1, and neutrophil gelatinase-associated lipocalin can be used as biomarkers to aid activity and diagnosis in ocular Behçet's disease.

Authors:  Fatih Celik; Ebru Coteli; Fatih Cem Gul; Ercan Ozsoy; Sabiha Gungor Kobat; Zuhal Karaca Karagoz; Suna Aydin; Kader Ugur; Meltem Yardim; İbrahim Sahin; Mehmet Hanifi Yalcin; Ramazan Fazil Akkoc; Suleyman Aydin
Journal:  Int Ophthalmol       Date:  2022-05-27       Impact factor: 2.029

6.  Thiol/disulfide homeostasis in patients with ocular-active and ocular-inactive Behçet disease.

Authors:  Mehmet Balbaba; Fatih Ulaş; Hakan Yıldırım; Adem Soydan; Ali Dal; Süleyman Aydın
Journal:  Int Ophthalmol       Date:  2020-06-01       Impact factor: 2.031

7.  Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments.

Authors:  Giacomo Emmi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2019-07-17       Impact factor: 3.397

8.  Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease.

Authors:  Giuseppe Lopalco; Vincenzo Venerito; Luca Cantarini; Giacomo Emmi; Domenico Prisco; Florenzo Iannone
Journal:  Intern Emerg Med       Date:  2018-10-25       Impact factor: 3.397

Review 9.  Vascular Behçet's syndrome: an update.

Authors:  Giacomo Emmi; Alessandra Bettiol; Elena Silvestri; Gerardo Di Scala; Matteo Becatti; Claudia Fiorillo; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2018-11-29       Impact factor: 3.397

10.  Does illness perception associate with disease symptoms in Behçet's disease?

Authors:  Gonca Mumcu; Fedayi Yağar; Fatma Alibaz-Öner; Nevsun İnanç; Haner Direskeneli; Tulin Ergun
Journal:  Intern Emerg Med       Date:  2018-11-30       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.